Literature DB >> 9210033

Sites other than nucleotide 234 determine cardiovirulence in natural isolates of coxsackievirus B3.

N M Chapman1, J R Romero, M A Pallansch, S Tracy.   

Abstract

The genetic site(s) that naturally determine the cardiovirulence phenotype of coxsackievirus B3 (CVB3) have yet to be mapped. Using two closely related CVB3 strains that differed in terms of cardiovirulence phenotype in mice, we previously reported the difference in phenotype mapped to a single site, nucleotide 234 (nt234) in the 5' non-translated region (NTR) of the CVB3 genome. When nt234 was C, the virus was attenuated and when U, the virus was cardiovirulent. To determine whether this finding was applicable to other strains of CVB3, we examined 13 different naturally occurring CVB3 strains isolated in different years in the United States. We determined that only two isolates induced severe inflammatory heart muscle disease in C3H/HeJ male mice. Using PCR products as sequencing templates, we determined the 5' NTR sequence from each viral genome. Alignment of these sequences and other published CVB3 5' NTR sequences suggests as many as four separate lineages, with commonly used laboratory strains clustering closely in one branch. An examination of the sequences showed that regardless of cardiovirulence phenotype, nt234 was invariably uridine. Thus, the previously reported cytidine at nt234 is most likely the result of a rare mutation and is not a naturally occurring variation and other sites must account for the variance in virulence seen in natural isolates of CVB3.

Entities:  

Mesh:

Year:  1997        PMID: 9210033

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Expression of the coxsackievirus and adenovirus receptor in cultured human umbilical vein endothelial cells: regulation in response to cell density.

Authors:  S D Carson; J T Hobbs; S M Tracy; N M Chapman
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice.

Authors:  N M Chapman; K S Kim; S Tracy; J Jackson; K Höfling; J S Leser; J Malone; P Kolbeck
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: localization to the 5' nontranslated region.

Authors:  J J Dunn; N M Chapman; S Tracy; J R Romero
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Expression of an antigenic adenovirus epitope in a group B coxsackievirus.

Authors:  K Höfling; S Tracy; N Chapman; K S Kim; J Smith Leser
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  An aged host promotes the evolution of avirulent coxsackievirus into a virulent strain.

Authors:  Raina T Gay; Sarah Belisle; Melinda A Beck; Simin Nikbin Meydani
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-01       Impact factor: 11.205

6.  Biological significance of a human enterovirus B-specific RNA element in the 3' nontranslated region.

Authors:  Ingrid Merkle; Mark J M van Ooij; Frank J M van Kuppeveld; Dirk H R F Glaudemans; Jochem M D Galama; Andreas Henke; Roland Zell; Willem J G Melchers
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Molecular Aspects of Myocarditis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.663

8.  Mutations in the 5' NTR and the Non-Structural Protein 3A of the Coxsackievirus B3 Selectively Attenuate Myocarditogenicity.

Authors:  Chandirasegaran Massilamany; Arunakumar Gangaplara; Rakesh H Basavalingappa; Rajkumar A Rajasekaran; Hiep Vu; Jean-Jack Riethoven; David Steffen; Asit K Pattnaik; Jay Reddy
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

Review 9.  The Roles of Picornavirus Untranslated Regions in Infection and Innate Immunity.

Authors:  Anna Kloc; Devendra K Rai; Elizabeth Rieder
Journal:  Front Microbiol       Date:  2018-03-20       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.